Surineni Goverdhan, Gao Yamin, Hussain Muzammal, Liu Zhiyong, Lu Zhili, Chhotaray Chiranjibi, Islam Md Mahmudul, Hameed H M Adnan, Zhang Tianyu
State Key Laboratory of Respiratory Disease , Guangzhou Institutes of Biomedicine and Health (GIBH) , Chinese Academy of Sciences (CAS) , Guangzhou-510530 , China . Email:
University of Chinese Academy of Sciences (UCAS) , Beijing , China.
Medchemcomm. 2018 Oct 25;10(1):49-60. doi: 10.1039/c8md00389k. eCollection 2019 Jan 1.
Tuberculosis (TB) has become one of the most significant public health problems in recent years. Antibiotic therapy remains the mainstay of TB control strategies, but the increasing resistance of mycobacterial species has heightened alarm, requiring the development of novel drugs in order to improve treatment outcomes. Here, as an effort to identify novel and effective antitubercular agents, we designed and synthesized a series of novel substituted benzimidazolallylidenehydrazinylmethylthiazole derivatives a multi-component molecular hybridization approach with single molecular architecture. Our design strategy involved assembling the antitubercular pharmacophoric fragments benzimidazole, 2-aminothiazole and substituted α,β-unsaturated ketones condensation reactions. All the newly synthesized compounds were fully characterized NMR and mass spectral data and evaluated for biological activity against the H37Ra strain of . From the biological evaluation data, we identified some effective compounds, of which and were the most active ones (both having MIC values of 2.5 μg mL). In addition, compound exhibited a lower cytotoxicity profile. We conceive that compound may serve as a chemical probe of interest for further lead optimization studies with the general aim of developing novel and effective antitubercular agents.
近年来,结核病已成为最重要的公共卫生问题之一。抗生素治疗仍然是结核病控制策略的主要手段,但分枝杆菌物种耐药性的增加引发了高度警惕,需要开发新型药物以改善治疗效果。在此,作为寻找新型有效抗结核药物的一项工作,我们设计并合成了一系列新型取代苯并咪唑亚苄基肼基甲基噻唑衍生物——一种具有单分子结构的多组分分子杂交方法。我们的设计策略包括通过缩合反应组装抗结核药效基团片段苯并咪唑、2-氨基噻唑和取代的α,β-不饱和酮。所有新合成的化合物均通过核磁共振和质谱数据进行了全面表征,并针对结核分枝杆菌H37Ra菌株评估了其生物活性。根据生物活性评估数据,我们鉴定出了一些有效化合物,其中化合物[具体编号1]和[具体编号2]活性最高(两者的最低抑菌浓度值均为2.5 μg/mL)。此外,化合物[具体编号3]表现出较低的细胞毒性。我们认为化合物[具体编号3]可作为一种有价值的化学探针,用于进一步的先导优化研究,总体目标是开发新型有效抗结核药物。